Pimecrolimus 1 percent cream in the treatment of psoriasis in a child

Dermatology Online Journal

Volumn 12, Issue 2, 2006, Pages

  Mansouri, Parvin ^a   Farshi, Susan ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CALCIPOTRIOL; CORTICOSTEROID; PIMECROLIMUS; DERMATOLOGICAL AGENT; DRUG DERIVATIVE; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ACANTHOSIS; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; EYELID DISEASE; FEMALE; HUMAN; HUMAN TISSUE; PARAKERATOSIS; PHYSICAL EXAMINATION; PSORIASIS; PUSTULE; SCHOOL CHILD; SKIN BIOPSY; UNSPECIFIED SIDE EFFECT; CHILD; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; CHILD; DERMATOLOGIC AGENTS; FEMALE; HUMANS; PSORIASIS; TACROLIMUS;

EID: 33748459660     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol. 2001 Jun;26(4):314-20.
2. Christophers E. The immunopathology of psoriasis. Int Arch Allergy Immunol. 1996 Jul;110(3):199-206.
3. Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol. 2003 May;17(3):257-70.
4. Kohlmann WM, Urban W, Sterry W, Foerster J. Correlation of psoriasis activity with abundance of CD25+CD8+ T cells: conditions for cloning T cells from psoriatic plaques. Exp Dermatol. 2004 Oct;13(10):607-12.
5. Gupta AK, Chow M. Pimecrolimus: a J Eur Acad Dermatol Venereol. 2003 Sep;17(5):493-503.
6. Wolff K. Current concepts and review of pimecrolimus in the treatment of psoriasis. Dermatol Clin. 2004 Oct;22(4):461-5, ix-x.
7. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y; Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002 Jul;110(1 Pt 1):e2.
8. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol. 2001 Mar;144(3):507-13.
9. Mrowietz U, Wustlich S, Hoexter G, Graeber M, Brautigam M, Luger T. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol. 2003;83(5):351-3.
10. Scheinfeld N. The use of topical tacrolimus and pimecrolimus to treat psoriasis: a Dermatol Online J. 2004 Jul 15;10(1):3.
11. Mrowietz U, Graeber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, Christophers E. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol. 1998 Dec;139(6):992-6.
12. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, Zaias N, Chen DM, Parneix-Spake A, Hultsch T, Menter A. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol. 2004 Nov;51(5):731-8.
13. Gottlieb AB, Griffiths CE, Ho VC, Lahfa M, Mrowietz U, Murrell DF, Ortonne JP, Todd G, Cherill R, Marks I, Emady-Azar S, Paul CF; Multi-Centre Investigator Group. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol. 2005 Jun;152(6):1219-27.